NASDAQ:PETQ - PetIQ Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$26.73 +0.35 (+1.33 %)
(As of 07/22/2018 05:04 AM ET)
Previous Close$26.73
Today's Range$26.32 - $27.11
52-Week Range$17.03 - $29.24
Volume375,064 shs
Average Volume417,723 shs
Market Capitalization$647.18 million
P/E Ratio68.54
Dividend YieldN/A
BetaN/A
PetIQ logoPetIQ, Inc. develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements. The company provides its products primarily under the VetIQ, PetAction Plus, Advecta, PetLock Plus, and TruProfen brands. It sells its products through distributors as well as through retail stores, including approximately 40,000 retail pharmacy locations. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

Receive PETQ News and Ratings via Email

Sign-up to receive the latest news and ratings for PETQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PETQ
CUSIPN/A
Phone208-939-8900

Debt

Debt-to-Equity Ratio0.69
Current Ratio2.35
Quick Ratio1.09

Price-To-Earnings

Trailing P/E Ratio68.54
Forward P/E Ratio34.27
P/E Growth1.36

Sales & Book Value

Annual Sales$266.69 million
Price / Sales2.46
Cash Flow$0.4131 per share
Price / Cash64.70
Book Value$4.88 per share
Price / Book5.48

Profitability

EPS (Most Recent Fiscal Year)$0.39
Net Income$-3,490,000.00
Net Margins0.17%
Return on Equity11.39%
Return on Assets6.69%

Miscellaneous

Employees225
Outstanding Shares24,530,000
Market Cap$647.18

PetIQ (NASDAQ:PETQ) Frequently Asked Questions

What is PetIQ's stock symbol?

PetIQ trades on the NASDAQ under the ticker symbol "PETQ."

How were PetIQ's earnings last quarter?

PetIQ Inc (NASDAQ:PETQ) posted its quarterly earnings data on Tuesday, May, 15th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.05 by $0.04. The firm earned $115.10 million during the quarter, compared to analyst estimates of $108.54 million. PetIQ had a net margin of 0.17% and a return on equity of 11.39%. The business's revenue for the quarter was up 71.8% on a year-over-year basis. View PetIQ's Earnings History.

When is PetIQ's next earnings date?

PetIQ is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for PetIQ.

What price target have analysts set for PETQ?

6 equities research analysts have issued 1-year target prices for PetIQ's stock. Their predictions range from $26.00 to $32.00. On average, they anticipate PetIQ's share price to reach $28.40 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Ratings for PetIQ.

What is the consensus analysts' recommendation for PetIQ?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about PetIQ stock?

Here are some recent quotes from research analysts about PetIQ stock:
  • 1. According to Zacks Investment Research, "PetIQ, Inc. is a pet medication and wellness company. Its product consists of Rx Medications, OTC Medications and Supplies, Health and Wellness Products. The Company serves retail stores across the mass, club, grocery, pharmacy and e-commerce channels. PetIQ, Inc. is based in Eagle, United States. " (6/6/2018)
  • 2. Jefferies Financial Group Inc analysts commented, "PETQ printed a strong 1Q, incl. sales at the high end of guidance (provided 4/11) and EBITDA +4% vs. Street, amidst cautious sentiment from poor weather. FY18 guide was reiterated and encouraging commentary on 2Q should be enough despite GM % shortfall given low bar (29% short interest)." (5/16/2018)

Who are some of PetIQ's key competitors?

Who are PetIQ's key executives?

PetIQ's management team includes the folowing people:
  • Mr. Mccord Christensen, Chairman of Directors & CEO (Age 46)
  • Mr. John Newland, CFO & Corp. Sec. (Age 54)

When did PetIQ IPO?

(PETQ) raised $86 million in an initial public offering (IPO) on Friday, July 21st 2017. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies and William Blair acted as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

Has PetIQ been receiving favorable news coverage?

Media coverage about PETQ stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PetIQ earned a daily sentiment score of 0.24 on Accern's scale. They also assigned press coverage about the company an impact score of 46.36 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are PetIQ's major shareholders?

PetIQ's stock is owned by many different of institutional and retail investors. Top institutional shareholders include WASATCH ADVISORS INC (11.20%), DIVISION OF INVESTMENT, DEPARTMENT OF THE TREASURY, STATE OF NEW JERSEY (5.05%), Fred Alger Management Inc. (1.33%), Essex Investment Management Co. LLC (0.77%), Tokio Marine Asset Management Co. Ltd. (0.08%) and Creative Planning (0.06%). Company insiders that own PetIQ stock include John Newland, Mccord Christensen and Ronald Kennedy. View Institutional Ownership Trends for PetIQ.

Which institutional investors are buying PetIQ stock?

PETQ stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Essex Investment Management Co. LLC, Tokio Marine Asset Management Co. Ltd. and Creative Planning. View Insider Buying and Selling for PetIQ.

How do I buy shares of PetIQ?

Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PetIQ's stock price today?

One share of PETQ stock can currently be purchased for approximately $26.73.

How big of a company is PetIQ?

PetIQ has a market capitalization of $647.18 million and generates $266.69 million in revenue each year. The company earns $-3,490,000.00 in net income (profit) each year or $0.39 on an earnings per share basis. PetIQ employs 225 workers across the globe.

How can I contact PetIQ?

PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company can be reached via phone at 208-939-8900 or via email at [email protected]


MarketBeat Community Rating for PetIQ (NASDAQ PETQ)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about PetIQ and other stocks. Vote "Outperform" if you believe PETQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.